Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

RATIONALE Moxifloxacin has potent activity against Mycobacterium tuberculosis in vitro and in a mouse model of antituberculosis (TB) chemotherapy, but data regarding its activity in humans are limited. OBJECTIVES Our objective was to compare the antimicrobial activity and safety of moxifloxacin versus isoniazid during the first 8 weeks of combination therapy for pulmonary TB. METHODS Adults with sputum smear-positive pulmonary TB were randomly assigned to receive either moxifloxacin 400 mg plus isoniazid placebo, or isoniazid 300 mg plus moxifloxacin placebo, administered 5 days/week for 8 weeks, in addition to rifampin, pyrazinamide, and ethambutol. All doses were directly observed. Sputum was collected for culture every 2 weeks. The primary outcome was negative sputum culture at completion of 8 weeks of treatment. MEASUREMENTS AND MAIN RESULTS Of 433 participants enrolled, 328 were eligible for the primary efficacy analysis. Of these, 35 (11%) were HIV positive, 248 (76%) had cavitation on baseline chest radiograph, and 213 (65%) were enrolled at African sites. Negative cultures at Week 8 were observed in 90/164 (54.9%) participants in the isoniazid arm, and 99/164 (60.4%) in the moxifloxacin arm (P = 0.37). In multivariate analysis, cavitation and enrollment at an African site were associated with lower likelihood of Week-8 culture negativity. The proportion of participants who discontinued assigned treatment was 31/214 (14.5%) for the moxifloxacin group versus 22/205 (10.7%) for the isoniazid group (RR, 1.35; 95% CI, 0.81, 2.25). CONCLUSIONS Substitution of moxifloxacin for isoniazid resulted in a small but statistically nonsignificant increase in Week-8 culture negativity.

[1]  John L. Johnson,et al.  Population Pharmacokinetics of Levofloxacin, Gatifloxacin, and Moxifloxacin in Adults with Pulmonary Tuberculosis , 2007, Antimicrobial Agents and Chemotherapy.

[2]  N. Lounis,et al.  In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis , 1998, Antimicrobial Agents and Chemotherapy.

[3]  D. Mitchison,et al.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  Hongkongchestservicebritishme.  CONTROLLED TRIAL OF FOUR THRICE-WEEKLY REGIMENS AND A DAILY REGIMEN ALL GIVEN FOR 6 MONTHS FOR PULMONARY TUBERCULOSIS , 1981 .

[5]  D. Mitchison,et al.  Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.

[6]  J. Grosset,et al.  Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis , 2008, Antimicrobial Agents and Chemotherapy.

[7]  Alexander Kopp,et al.  Outpatient gatifloxacin therapy and dysglycemia in older adults. , 2006, The New England journal of medicine.

[8]  V. Nandi,et al.  Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy , 2006, Antimicrobial Agents and Chemotherapy.

[9]  B. Ji,et al.  Experimental Chemotherapy of Mycobacterial Diseases , 1998 .

[10]  D. Mitchison,et al.  Moxifloxacin and Gatifloxacin in an Acid Model of Persistent Mycobacterium tuberculosis , 2006, Journal of chemotherapy.

[11]  R. Stahlmann,et al.  Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. , 2004, Clinical therapeutics.

[12]  C. Truffot-Pernot,et al.  Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. , 1989, The American review of respiratory disease.

[13]  S. P. Tripathy.  Relapse in tuberculosis , 1981 .

[14]  A. Nunn,et al.  [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy]. , 1978, Bulletin of the International Union against Tuberculosis.

[15]  J. Gavin,et al.  Moxifloxacin and Glucose Homeostasis , 2004, Drug safety.

[16]  D. Mitchison.  Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. , 1993, The American review of respiratory disease.

[17]  J. Grosset,et al.  Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model , 2008, Antimicrobial Agents and Chemotherapy.

[18]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[19]  H. Lode,et al.  Comparative Pharmacokinetics of Ciprofloxacin, Gatifloxacin, Grepafloxacin, Levofloxacin, Trovafloxacin, and Moxifloxacin after Single Oral Administration in Healthy Volunteers , 2000, Antimicrobial Agents and Chemotherapy.

[20]  C. Daley,et al.  Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  A. Tice,et al.  Short-course therapy of acute cystitis: a brief review of therapeutic strategies. , 1999, The Journal of antimicrobial chemotherapy.

[22]  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis , 2002 .

[23]  D. Snydman.  Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis , 2007 .

[24]  C. Truffot-Pernot,et al.  Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice , 1993, Antimicrobial Agents and Chemotherapy.

[25]  W. Bishai,et al.  Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. , 2005, American journal of respiratory and critical care medicine.

[26]  R. Chaisson,et al.  Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[27]  R. Chaisson,et al.  Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[28]  S. Gillespie,et al.  The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[29]  Hong Kong Chest Servicebritish Medical Research Council.  CONTROLLED TRIAL OF FOUR THRICE-WEEKLY REGIMENS AND A DAILY REGIMEN ALL GIVEN FOR 6 MONTHS FOR PULMONARY TUBERCULOSIS , 1981, The Lancet.

[30]  William R Bishai,et al.  Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial , 2009, The Lancet.

[31]  J. T. Sullivan,et al.  Pharmacokinetics of a Once-Daily Oral Dose of Moxifloxacin (Bay 12-8039), a New Enantiomerically Pure 8-Methoxy Quinolone , 1999, Antimicrobial Agents and Chemotherapy.

[32]  Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. , 1972, Lancet.

[33]  R. Chaisson,et al.  Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[34]  R. Chaisson,et al.  Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model , 2007, PLoS medicine.

[35]  N. Lounis,et al.  Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice , 2001, Antimicrobial Agents and Chemotherapy.